Stock Traders Purchase High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the target of unusually large options trading on Monday. Traders bought 15,741 call options on the company. This is an increase of approximately 36% compared to the typical volume of 11,557 call options.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Capricor Therapeutics by 6.8% in the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after acquiring an additional 61,701 shares in the last quarter. Woodline Partners LP boosted its position in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after purchasing an additional 99,384 shares during the period. Pier Capital LLC increased its stake in shares of Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock worth $3,580,000 after purchasing an additional 128,837 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $4,270,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after purchasing an additional 116,373 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 12.8%

CAPR stock traded up $3.44 during midday trading on Monday, reaching $30.33. 3,730,161 shares of the company’s stock traded hands, compared to its average volume of 2,171,547. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37. The stock has a market cap of $1.39 billion, a P/E ratio of -17.04 and a beta of 0.62. The stock’s 50-day moving average is $7.59 and its 200 day moving average is $8.22.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). As a group, research analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. HC Wainwright increased their price objective on Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday. Roth Capital boosted their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Maxim Group raised their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.